Form 4: Vivani Medical Director Aaron Mendelsohn Granted 35,135 Stock Options

Vivani Medical, Inc. Director Aaron Mendelsohn was granted 35,135 non-qualified stock options at an exercise price of $1.27 per share as part of the company's non-employee director compensation policy.

Summary

• Aaron Mendelsohn, a Director of Vivani Medical, Inc. (VANI), was granted 35,135 non-qualified stock options.
• The options were granted on June 24, 2025, with an exercise price of $1.27 per share.
• This grant is an annual award under the Issuer's Non-Employee Director Compensation Policy.
• The options will vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service.
• The options have an expiration date of June 23, 2035.
• Following this transaction, Aaron Mendelsohn directly beneficially owns 35,135 derivative securities (stock options).
• A Limited Power of Attorney was executed on June 26, 2025, by Aaron Mendelsohn, appointing Adam Mendelsohn, Donald Dwyer, and Anthony Baldor as attorneys-in-fact to handle SEC filings on his behalf.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing, which is generally a neutral event. The grant of options aligns director interests with shareholders, which is a positive aspect of corporate governance.

Positives

• The granting of stock options aligns the director's interests with shareholders, incentivizing long-term performance.
• The option grant is part of a standard Non-Employee Director Compensation Policy, indicating a structured and transparent approach to executive compensation.

Risks

• Aaron Mendelsohn has agreed to indemnify the attorneys-in-fact and the Company from any demand, damage, loss, cost, or expense arising from any false or misleading information provided by him to the attorneys-in-fact, a standard legal clause in such agreements.

Future Outlook

The document primarily details a past transaction (grant of options) and a legal authorization (Power of Attorney). It does not contain forward-looking statements about company performance or strategic guidance.

Industry Context

This is a routine insider transaction filing (Form 4) related to director compensation. It reflects standard corporate governance practices for publicly traded companies, where non-employee directors receive equity compensation to align their interests with shareholders. This filing does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common practice across publicly traded companies, aligning director incentives with long-term shareholder value.
• The vesting schedule (earlier of first anniversary or next annual meeting) is typical for such grants, ensuring continued service.
• The exercise price being equal to the market price on the grant date (implied, as it's a grant) is standard for non-qualified options.

Corporate Governance

Related Party Transactions

• The grant of 35,135 non-qualified stock options to Aaron Mendelsohn, a director, constitutes a related party transaction, which is a standard form of compensation for non-employee directors.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value. It also represents a form of potential dilution if options are exercised, which is standard for equity compensation.

Next Steps

• The options will vest on the earlier of the first anniversary of the grant (June 24, 2026) or the next annual meeting of stockholders.
• Aaron Mendelsohn may exercise the options at any time after vesting until the expiration date of June 23, 2035.

Key Dates

Recommendation

Keywords

Vivani Medical, VANI, Stock Option Grant, Director Compensation, SEC Form 4, Beneficial Ownership, Non-Qualified Stock Option, Corporate Governance, Executive Compensation